Neumora Therapeutics, Inc. (NMRA) - Total Liabilities
Based on the latest financial reports, Neumora Therapeutics, Inc. (NMRA) has total liabilities worth $45.67 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Neumora Therapeutics, Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how Neumora Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Neumora Therapeutics, Inc. (NMRA) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Neumora Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Neumora Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Entrada Therapeutics Inc
NASDAQ:TRDA
|
USA | $72.18 Million |
|
Imperial Brands PLC
LSE:IMB
|
UK | GBX23.62 Billion |
|
Taiwan Sanyo Electric Co Ltd
TW:1614
|
Taiwan | NT$1.46 Billion |
|
Pecca Group Bhd
KLSE:5271
|
Malaysia | RM50.27 Million |
|
Ginwa Enterprise Group Inc
SHG:600080
|
China | CN¥370.80 Million |
|
EnviTec Biogas AG
XETRA:ETG
|
Germany | €237.48 Million |
|
Teamlease Services Limited
NSE:TEAMLEASE
|
India | Rs17.41 Billion |
|
Hanoi Beer Alcohol and Beverage JSC
VN:BHN
|
Vietnam | ₫1.74 Trillion |
Liability Composition Analysis (2019–2024)
This chart breaks down Neumora Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Neumora Therapeutics, Inc. market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neumora Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neumora Therapeutics, Inc. (2019–2024)
The table below shows the annual total liabilities of Neumora Therapeutics, Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $29.91 Million | +10.28% |
| 2023-12-31 | $27.12 Million | -96.89% |
| 2022-12-31 | $873.08 Million | +15.71% |
| 2021-12-31 | $754.52 Million | +158.10% |
| 2020-12-31 | $292.33 Million | +1391947.62% |
| 2019-12-31 | $21.00K | -- |
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive diso… Read more